Amanta Healthcare Ltd — earnings calls

Amanta Healthcare reported Q1 FY27 revenue of INR69 crores, up roughly 5% year-on-year, with EBITDA of about INR15 crores and an EBITDA margin of approximately 22%. Management attributed cost pressure to a polymer price spike linked to the Middle East crisis and to overheads absorbed ahead of the delayed SteriPort Line 3 commissioning. The company detailed capex, timelines and expected margin impact from the SteriPort expansion, the SVP facility, and the newly commissioned captive solar power plant.

Amanta Healthcare reported FY26 revenue of INR288 crores and EBITDA of INR63 crores at around 22% margin, with PAT growing over 42% year-on-year. Management said the SteriPort platform contributed nearly 42% of revenue from operations and detailed a capacity expansion from 6.6 crore to roughly 12 crore bottles per year expected to be commissioned by June 20. Management also discussed rising polymer input costs of 60-70%, which they said have been offset through price revisions, and outlined debt reduction with the debt-to-equity ratio improving from 3x to nearly 1x.